Health
The US approved lecanemab to slow cognitive decline among people with early Alzheimer’s, but not everyone is convinced the drug has that big of an impact – not to mention concerns over its safety and practicality
By Grace Wade
MRI scans of a healthy brain (left) and a brain with amyloid plaque deposits (right), a sign of Alzhiemer’s disease
MARK AND MARY STEVENS NEUROIMAGING AND INFORMATICS INSTITUTE/SCIENCE PHOTO LIBRARY
Some hailed 2023 as the beginning of a turning point in our efforts to combat Alzheimer’s disease. Two countries – the US and Japan – approved a drug called lecanemab, the first treatment that actually slows the condition’s progression, rather than just easing its symptoms. Many other countries, including the UK and Australia, are now considering following suit, but the drug isn’t without its critics.
Lecanemab gained approval in…
View introductory offers
No commitment, cancel anytime*
Offer ends 28th October 2023.
*Cancel anytime within 14 days of payment to receive a refund on unserved issues.
Inclusive of applicable taxes (VAT)
or
Existing subscribers
Sign in to your account
More from New Scientist
Explore the latest news, articles and features
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : New Scientist – https://www.newscientist.com/article/2408994-2023-saw-a-cautious-hope-for-alzheimers-treatment-but-doubts-remain/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=home
Why David Brooks Is Choosing to Step Back from Politics-And What It Means